News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Goutham Sunny: Vonafexor in HBV+ HCC – A Game-Changer?
Goutham Sunny/LinkedIn
Jul 2, 2025, 09:48

Goutham Sunny: Vonafexor in HBV+ HCC – A Game-Changer?

Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X about a paper by Banglun Pan et al. published in the British Journal of Cancer:

“Vonafexor in HBV+ HCC: A Game-Changer?
Study Highlights:
Researchers modeled HBV+ HCC using patient-derived tumors in humanized mice to explore Vonafexor’s role beyond antiviral effects.
Key Findings:
  • Inhibits CD36-mediated fatty acid uptake in tumor cells, promoting sublethal damage
  • Boosts T and NK cell cytotoxicity by enhancing GZMB via cGAS-STING-NF-κB signaling
  • Reduces immune suppression by blocking MDSC infiltration through inhibition of c-Rel nuclear entry
  • Lowers HBV e-antigen, improving mitochondrial ROS signaling
Pros:
  • Dual action: Antiviral + Immunomodulatory
  • Targets metabolic vulnerability of HBV+ HCC
  • Enhances innate and adaptive immunity
  • Reduces immunosuppressive cell populations
Cons:
  • Preclinical; needs human validation
  • Mechanisms complex and may vary with patient heterogeneity
  • Unclear durability of immune activation
Significance:
Vonafexor shows promise as a novel immunotherapeutic for HBV-related liver cancer by reshaping the tumor immune microenvironment. Could represent a paradigm shift in targeting virus-associated cancers.”

Title: New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity

Authors: Banglun Pan, Siyan Chen, Zhu Zhang, Dongjie Ye, Xiaoxia Zhang, Yuxin Yao, Yue Luo, Hao Wu, Xiaoqian Wang and Nanhong Tang

You can read the Full Article in the British Journal of Cancer.

Goutham Sunny: Vonafexor in HBV+ HCC - A Game-Changer?

More posts featuring Goutham Sunny.

Banglun Pan cancer Dongjie Ye Goutham Sunny Hao Wu HBV+ HCC HCC Nanhong Tang OncoDaily Oncology Siyan Chen Vonafexor Xiaoqian Wang Xiaoxia Zhang Yue Luo Yuxin Yao Zhu Zhang
Special Coverage
Oncolibrary
Jul 2, 2025, 14:52
ESMO GI 2025 Highlights: SIERRA Study on STRIDE in Unresectable HCC
Blog
Jul 2, 2025, 14:43
CancerWorld #105: Shaping the Future of Oncology Amid Conflict, Innovation, and Equity
Oncolibrary
Jul 2, 2025, 14:00
ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC
Blog
Jul 2, 2025, 13:41
Kenji López-Cuevas Congratulates Andreas Charalambous on His Appointment as Chairman of the SPCC
Blog
Jul 2, 2025, 13:25
Julie Ince-Demetriou: On 7th July Inaugural Pink Sky Grants Scheme Will Open to EOI Applications
Blog
Jul 2, 2025, 13:19
Korede Akindele: Sarcoma May Be Rare But Survival Shouldn’t Be
Blog
Jul 2, 2025, 13:08
Irini Agapidaki on the Critical Role of Prevention and the National Program 'Prolamvano'
Blog
Jul 2, 2025, 12:57
Mehmet Murat Zerey: I am Starting a New Position as an Advanced Genitourinary Oncology Clinical Fellow at Vanderbilt University Medical Center
Insight
Jul 2, 2025, 12:37
Wafaa M Rashed: New on the PAPERI Blog - Epigenetics and Maternal Nutrition in Africa as a Public Health Priority
Blog
Jul 2, 2025, 12:32
Sergio Cifuentes Canaval: What it Means to Build a Career in Oncology From Latin America
Blog
Jul 2, 2025, 12:21
We Managed to Give Unforgettable Moments to Girls and Boys of the Hospital Infantil of Mexico 'Federico Gómez' - Cancer Warriors Foundation of Mexico
Blog
Jul 2, 2025, 11:46
Lucrecia Ruiz: I’m Starting a New Position as Head of the Melanoma, Head and Neck Cancer, and Neuro-Oncology Section at MD Anderson Madrid